The prospects for renal xenotransplantation

Nephrology

Volumn 2, Issue 4, 1996, Pages 217-227

  Van Denderen, Bryce J W ^a   Pearse, Martin J ^a   D'Apice, Anthony J F ^a  

^a ST VINCENT S HOSPITAL   (Australia)

Author keywords

Complement; Hyperacute rejection; Natural antibodies; Xenotransplantation

Indexed keywords

EID: 0345179498     PISSN: 13205358     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1797.1996.tb00091.x     Document Type: Article

References (123)

1. Disney APS. ANZDATA Report 1995. Adelaide, SA: Australia and New Zealand Dialysis and Transplant Registry, 1995.
2. Reemtsma K, McCracken BH, Schlegel JY et al. Renal hetetotransplantation in man. Ann. Surg. 1964; 160: 384-410.
3. Starzl TE, Marchioro TL, Peters GN et al. Renal heterotransplantation from baboon to man: Experience with 6 cases. Transplantation 1964; 2: 752-76.
4. Hitchcock CR, Kiser JC, Telander RL, Seljeskog EL. Baboon renal grafts. JAMA 1964; 189: 158-61.
5. Bailey LL, Nehlsen-Cannarella SL, Concepcion W, Jolley WB. Baboon-to-human cardiac xenotransplantation in a neonate. JAMA 1985; 254: 3321-9.
6. Starzl TE, Fung J, Tzakis A et al. Baboon to human liver transplantation. Lancet 1993; 341: 65-71.
7. Starzl TE, Valdivia LA, Murase N et al. The biological basis of and strategies for clinical xenotransplantation. Immunol. Rev. 1994; 141: 213-44.
8. Van der Riet FDJ, Human PA, Cooper DKC et al. Virological implications of the use of primates in xenotransplantation. Transplant. Proc. 1987; 19: 4068-9.
9. Michaels MG, Simmons RL. Xenozoonoses: Possible xenotransplant-associated infections. Xeno. 1994; 2: 47-51.
10. Michaels MG, McMichael JP, Brasky K et al. Screening donors for xenotransplantation. The potential for xenozoonoses. Transplantation 1994; 57: 1462-5.
11. Cooper DKC, Ye Y, Rolf JLL, Zuhdi N. The pig as a potential organ donor for man. In: Cooper DKC, Kemp E, Reemtsma K, White DJG. (eds). Xenotransplantation. Springer-Verlag, Heidelberg, 1991; 481-500.
12. Ye Y, Niekrasz M, Kosanke S et al. The pig as a potential organ donor for man. A study of potentially transferable disease from donor pig to man. Transplantation 1994; 57: 694-703.
13. Calne RY. Organ transplantation between widely disparate species. Transplant. Proc. 1970; 2: 550-6.
14. Hancock WW, Bach FH. The immunopathology of discordant xenograft rejection. Xeno. 1994; 2: 68-74.
15. Forbes RDC, Guttmann RD. Histopathology and mechanism of rejection in xenotransplantation. In: Hardy M. (ed). Xenograft 25. Elsevier Science Publishers, Amsterdam, 1989; 133-47.
16. Ross JR, Kirk AD, Ibrahim SE, Howell DN, Baldwin WM, Sanfilippo FP. Characterization of human anti-porcine 'natural antibodies' recovered from ex-vivo perfused hearts. Predominance of IgM and IgG2. Transplantation 1993; 55: 1144-50.
17. Platt JL, Fischel RJ, Matas AJ, Reif SA, Bolman RM, Bach FH. Immunopathology of hyperacute xenograft rejection in a swine-to-primate model. Transplantation 1991; 52: 214-20.
18. Babinet C, Morello D, Renard JP. Transgenic mice. Genome 1989; 31: 938-49.
19. Brewer RJ, Del Rio MJ, Roslin MS et al. Depletion of preformed antibody in primates for discordant xenotransplantation by continuous donor organ plasma perfusion. Transplant. Proc. 1993; 25: 385-6.
20. Sandrin MS, Vaughan HA, Dabkowski PL, McKenzie IFC. Anti-pig IgM antibodies in human serum react predominantly with Gal(α1-3)gal epitopes. Proceedings of the National Academy of Science USA. 1993; 90: 11391-5.
21. Vaughan HA, Loveland BE, Sandrin MS. Gal α(1,3)gal is the major xenoepitope expressed on pig endothelial cells recognized by naturally occurring cytotoxic human antibodies. Transplantation 1994; 58: 879-82.
22. Oriole R, Ye Y, Koren E, Cooper DKC. Carbohydrate antigens on pig tissues reacting with human natural antibodies as potential targets for hyperacute rejection in pig-to-man organ xenotransplantation. Transplantation 1993; 56: 1433-42.
23. Platt JL, Lindeman BJ, Chen H, Spitalnik SL, Bach FH. Endothelial cell antigens recognised by xenoreactive human natural antibodies. Transplantation 1990; 50: 817-22.
24. Galili U, Shohet SB, Korbin E, Stults CLM, Macher BA. Man, apes and old world monkeys differ from other mammals in the expression of α-galactosyl epitopes on nucleated cells. J. Biol. Chem. 1988; 263: 17555-762.
25. Galili U, Swanson K. Gene sequences suggest inactivation of alpha-1,3-galactosyltransferase in catarrhines after the divergence of apes from monkeys. Proc. Natl Acad. Sci. USA 1991; 88: 7401-4.
26. Galili U, Mandrell RE, Hamadeh RM, Shohet SB, Griffins JM. Interaction between human natural anti-α-galactosyl Immunoglobulin G and bacteria of the human flora. Immun. Infect. 1988; 56: 1730-7.
27. Platt JL, Lindman BJ, Geller RL et al. The role of natural antibodies in the activation of xenogeneic endothelial cells. Transplantation 1991; 52: 1037-43.
28. Gambiez L, Salame E, Chereau C et al. The role of natural IgM in the hyperacute rejection of discordant heart xenografts. Transplantation 1992; 54: 577-83.
29. Inveradi L, Samaja M, Motterlini R, Mangili F, Bender J, Pardi R. Early recognition of a discordant xenogeneic organ by human circulating lymphocytes. J. Immunol. 1992; 149: 1416-23.
30. Agishi T, Takahashi K, Ota K, Tagisawa T. Comparative evaluation of immunoabsorption and double filtration plasmapheresis for removal of anti-A or anti-B antibody in ABO-incompatible kidney transplantation. Transplant. Proc. 1992; 24: 557-8.
31. Besse T, Duck L, Latinne D et al. Effect of plasmapheresis and splenectomy on parameters involved in vascular rejection of discordant xenografts in the swine to baboon model. Transplant. Proc. 1994; 17: 1042-4.
32. Leventhal JR, John R, Fryer JP et al. Removal of baboon and human antiporcine IgG and IgM natural antibodies by immunoadsorption. Transplantation 1995; 59: 294-300.
33. Neethling FA, Koren E, Ye Y et al. Protection of pig kidney (PK15) cells from the cytotoxic effect of anti-pig antibodies by α-galactosyl oligosaccharides. Transplantation 1994; 57: 959-63.
34. Henry ML, Han LK, Davies EA, Orosz CG, Sedmak DD, Ferguson RM. The role of organ perfusion in xenotransplantation: Influence of ex vivo xenoantibody absorption on xenograft survival. In: Hardy MA. (ed). Xenograft 25. Elsevier Science Publishers (Biomedical Division), Amsterdam, 1989; 249-58.
35. Cooper DKC, Koren E, Oriol R. Oligosaccharides and discordant xenotransplantation. Immunol Rev. 1994; 141: 31-58.
36. Latinne D, Soares M, Havaux X et al. Depletion of IgM xenoreactive natural antibodies by injection of anti-μ, monoclonal antibodies. Immunol Rev. 1994; 141: 95-125.
37. Soares M, Havaux X, Latinne D, Bazin H. Depletion of xenoreactive natural antibodies by anti-μ, monoclonal antibodies. Xeno. 1994; 2: 88-92.
38. Parker W, Bruno D, Holzknecht ZE, Platt JL. Characterization and affinity isolation of xenoreactive human natural antibodies. J. Immunol. 1994; 153: 3791-803.
39. Tearle RG, Tange MJ, Zannettino ZL et al. The α-1,3-Galactosyltransferase knockout mouse: Implications for xenotransplantation. Transplantation 1995; 61: 13-9.
40. Sandrin MS, Mouhtouris E, Osman N, Fodor WL, Squinto SP. Elimination of the major porcine xenoantigen, Gal α(1,3) Gal, by expression of α(1,2) fucosyltransferase. Glycoconjugate J. 1995; 12: 468.
41. Sandrin MS, Fodor WL, Mouhtouris E et al. Enzymatic remodelling of the carbohydrate surface of a xenogenic cell substantially reduces human antibody binding and complement-mediated cytolysis. Nature Med. 1995; 1: 1261-7.
42. Chen C-G, Fisicaro N, Shinkel TA et al. Reduction in gal-α1,3-gal epitope expression in transgenic mice expressing human H-transferase. Xenotransplamanon 1996; 28: 625-6.
43. d'Apice AJF, Tange MJ, Chen C-G, Cowan P, Shinkel TA, Pearse MJ. The Gal α1,3 Gal xenoantigen: Elimination, suppression, masking or none of the above? Xeno 1996 (in press).
44. Strahan KM, Preece AF, Xu Y, Gustafsson K. Antisense inhibition of pig α1,3galactosyl-transferase leads to a reduction in expression of the major target for human natural antibodies on pig vascular endothelial cells. Xenotransplantation 1995; 2: 143-7.
45. Alexandre GPJ, Squifflet JP, De Bruyere M et al. Present experiences in a series of 26 ABO-incompatible living related allografts. Transplant. Proc. 1987; 19: 4538-42.
46. Palmer A, Welsh K, Gjorstrup P, Taube D, Bewick M, Thick M. Removal of anti-HLA antibodies by extracorporeal immunoadsorption to enable renal transplantation. Lancet 1989; 1: 10-2.
47. Platt JL, Vercelloti GM, Dalmasso AP et al. Transplantation of discordant xenografts: a review of progress. Immunol. Today 1990; 11: 450-6.
48. Alexandre GPJ, Gianello P, Latinne D et al. Plasmapheresis and splenectomy in experimental renal xenotransplantation. In: Hardy MA. (ed). Xenograft 25. Elsevier Science Publishers, Amsterdam, 1989; 259-66.
49. Levanthal JR, Dalmasso AP, Cromwell JW et al. Prolongation of cardiac xenograft survival by depletion of complement. Transplantation 1993; 55: 857-66.
50. Pruitt SK, Kirk AD, Bollinger RR et al. The effect of soluble complement receptor type 1 on hyperacute rejection of porcine xenografts. Transplantation 1994; 57: 363-70.
51. Zhow X-J, Niesen N, Pawlowski I et al. Prolongation of survival of discordant kidney xenografts by C6 deficiency. Transplantation 1990; 50: 896-8.
52. Brauer RB, Baldwin WM, Daha MR, Pruitt SK, Sanfilippo F. Use of C6-deficient rats to evaluate the mechanism of hyperacute rejection of discordant cardiac xenografts. J. Immunol. 1993; 151: 7240-8.
53. Brauer RB, Baldwin WM, Sanfilippo F. Complement-deficient animals in the study of Hyperacute rejection. Xeno. 1994; 2: 35-7.
54. Miyagawa S, Hirose H, Shirakura R et al. The mechanism of discordant xenograft rejection. Transplantation 1988; 46: 825-30.
55. Otte KE, Andersen N, Jorgensen KA et al. Xenoperfusion of pig kidney with human AB or O whole blood. Transplant. Proc. 1990; 22: 1091-2.
56. Johnston PS, Wang M-W, Lim SM, Wright LJ, White DJG. Discordant xenograft rejection in an antibody-free model. Transplantation 1992; 54: 573-6.
57. Farries TT, Steuer KLK, Atkinson JP. The mechanism of activation of the alternative pathway by cell-bound C4b. Mol. Immunol. 1990; 27: 1155-61.
58. Weill BJ, Regimbeau J-M, Calmus Y, Chereau C, Houssin D. The alternative complement pathway in hyperacute xenograft rejection. Xeno. 1994; 2: 92-4.
59. Dalmasso AP. The complement system in xenotransplantation. Immunopharmocology 1992; 24: 149-60.
60. Baldwin WM, Pruitt SK, Brauer RB, Daha MR, Sanfilippo F. Complement in organ transplantation. Transplantation 1995; 59: 797-808.
61. Platt JL, Dalmasso AP, Lindeman BJ, Ihrcke NS, Bach FH. The role of C5a and antibody in the release of heparan sulphate from vascular endothelial cells. Eur. J. Immunol. 1991; 21: 2887-90.
62. Morgan BP. Mechanisms of tissue damage by the membrane attack complex of complement. Complement Inflamm. 1989; 6: 104-11.
63. Carney DF, Lang TJ, Shin. M L. Multiple signal messengers generated by terminal complement complexes and their role in terminal complement complex elimination. J. Immunol. 1990; 145: 623-9.
64. Morgan BP, Meri S. Membrane proteins that protect against complement lysis. Springer Sem. Immunopathology 1994; 15: 369-96.
65. Nicholson-Weller A. Deficiencies of the decay accelerating factor (DAF) and the C8-binding protein in paroxysmal nocturnal haemoglobinuria. In: Kazatchkine MD (ed.). Complement and immunological disease, vol 2. Bailliere Tindall, London, 1988; 477-88.
66. Nickells MW, Alvarez JI, Lublin DM, Atkinson JP. Characterization of DAF-2, a high molecular weight form of decay-accelerating factor (DAF; CD55), as a covalently cross-linked dimer of DAF-1. J. Immunol. 1994; 152: 676-85.
67. Nonaka M, Miwa T, Okada N, Nonaka M, Okada H. Multiple isoforms of guinea pig decay-accelerating factor (DAF) generated by alternative splicing. J. Immunol. 1995; 155: 3037-48.
68. Spicer AP, Seldin MF, Gendler SJ. Molecular cloning and chromosomal localization of the mouse decay-accelerating factor genes. J. Immunol. 1995; 155: 3079-91.
69. Dalmasso AP, Vercellotti GM, Platt JL, Bach FH. Inhibition of complement-mediated endothelial cell cytotoxicity by decay-accelerating factor. Transplantation 1991; 52: 530-1.
70. Kennedy SP, Rollins SA, Burton WV et al. Protection of porcine aortic endothelial cells from complement-mediated cell lysis and activation by recombinant human CD59. Transplantation 1994; 57; 1494-501.
71. van Denderen BJW, Pearse MJ, Katerelos M et al. Expression of functional decay-accelerating factor (CD55) in transgenic mice protects against human complement-mediated attack. Transplantation 1996.
72. Mulder LCF, Mora M, Ciccopiedi E et al. Mice transgenic for human CD46 and CD55 are protected from human complement attack. Transplant. Proc. 1995; 27: 333-5.
73. Cary N, Moody J, Yannoutsos N, Wallwork J, White D. Tissue expression of human decay accelerating factor, a regulator of complement activation expressed in mice: A potential approach to inhibition of hyperacute xenograft rejection. Transplant. Proc. 1993; 25: 400-1.
74. Thorley BR, Milland J, McInnes B, Christiansen D, McKensie IFC, Loveland BE. Transgenic expression of CD46 mice: A potential role in xenotransplanation. The Transplantation Society of Australia and New Zealand, Canberra, 1995.
75. Somerville CA, Kyriazis AG, McKensie A, Allison J, Pearse MJ, d'Apice AJF. Functional expression of human CD59 in transgenic mice. Transplantation 1994; 58: 1430-5.
76. Diamond LE, Oldham ER, Platt JL et al. Cell- and tissue-specific expression of a human CD59 minigene in transgenic mice. Transplant. Proc. 1994; 26: 1239.
77. Fodor WL, Williams BL, Matis LA et al. Expression of a functional human complement inhibitor in a transgenic pig as a model for the prevention of xenogeneic hyperacute organ rejection. Proc. Natl Acad. Sci. USA 1994; 91: 11 153-7.
78. Diamond LE, McCurry KR, Oldham ER et al. Human CD59 expressed in transgenic mouse hearts inhibits the activation of complement. Transplant Immunol. 1995; 3: 305-12.
79. Kooyman DL, Byrne GW, McClellan S et al. In vivo transfer of GPI-linked complement restriction factors from erythrocytes to the endothelium. Science 1995; 269: 89-92.
80. Pearce EJ, Hall BF, Sher A. Host-specific evasion of the alternative complement pathway by schistosomes correlates with the presence of a phospholipase C-sensitive surface molecule resembling human decay accelerating factor. J. Immunol. 1990; 144: 2751-6.
81. Fatima M, Horta M, Ramalho-Pinto FJ. Role of human decay-accelerating factor in the evasion of Schistosoma mansoni from the complement-mediated killing in vitro. J. Exp. Med. 1991; 174: 1399-406.
82. Parizade M, Lachmann PJ, Arnon R, Fichelson Z. A protectin (CD59)-like molecule on the surface of Schistosoma mansoni. Complement Inflamm. 1991; 8: 205.
83. McCurry KR, Kooyman DL, Diamond LE, Byrne GW, Logan JS, Platt JL. Transgenic expression of human complement regulatory proteins in mice results in diminished complement deposition during organ xenoperfusion. Transplantation 1995; 59: 1177-82.
84. McCurry KR, Kooyman DL, Alvarado CG et al. Human complement regulatory proteins protect swine-to-primate xenografts from humoral injury. Nature Med. 1995; 1: 423-7.
85. Fodor WL, Squinto SP. Engineering of transgenic pigs for xenogeneic organ transplantation. Xeno. 1995; 3: 23-5.
86. Rosengard AM, Cary NRB, Langford GA, Tucker AW, Wallwork J, White DJG. Tissue expression of human complement inhibitor, decay-accelerating factor (DAF), in transgenic pigs - a potential approach for preventing xenograft rejection. Transplantation 1995; 59: 1325-33.
87. White DJG, Langford GA, Cozzi E, Young VJ. Protective effects of human DAF in transgenic pigs. Xeno. 1995; 3: 48-51.
88. White DJG, Braidley P, Dunning J et al. Hearts from pigs transgenic for human DAF are not hyperacutely rejected when xenografted to primates. The Third International Congress for Xenotransplantation, Boston, Massachusetts, 1995: Plenary #19.
89. Lexer G, Cooper DKC, Rose AG. Hyperacute rejection in a discordant (pig to baboon) cardiac xenograft model. J. Heart Transplant. 1986; 5: 411.
90. Regal JF. Enhancement of antigen-induced bronchoconstriction in the guinea pig after intravascular complement activation with cobra venom factor. Int. Arch. Allergy Appl. Immunol. 1990; 91: 86-94.
91. Leventhal JR, Sakiyalak P, Witson J et al. The synergistic effect of combined antibody and complement depletion on discordant cardiac xenograft survival in nonhuman primates. Transplantation. 1994; 57: 974-8.
92. Weiler JM, Edens RE, Linhardt RJ, Kapelanski DP. Heparin and modified heparin inhibit complement activation in vivo. J. Immunol. 1992; 148: 3210-5.
93. Carrobi A, Distefano R, Danesi R et al. Suramin as an anticomplementary agent in xenotransplantation. Transplant. Proc. 1992; 24: 700.
94. Miyagawa S, Shirakura R, Matsumiya G et al. Prolonging discordant xenograft survival with anticomplement reagents K76COOH and FUT175. Transplantation 1993; 55: 709-13.
95. Moran P, Beasley H, Gorrel A et al. Human recombinant soluble decay accelerating factor inhibits complement activation in vitro and in vivo. J. Immunol. 1992; 149: 1736-43.
96. Loveland BE, Christiansen D, Milland J et al. Production and characterization of recombinant soluble CD46, an effective complement regulator in vitro and in vivo. The Third International Congress for Xenotransplantation, Boston, Massachusetts, 1995: Abstract #230.
97. Pruitt SK, Bollinger RR. The effect of soluble complement receptor type 1 on hyperacute allograft rejection. J. Surg. Res. 1991; 50: 350-5.
98. Pruitt SK, Baldwin WM, Marsh HC, Lin SS, Yeh CG, Bollinger RR. The effect of soluble complement receptor type 1 on hyperacute xenograft rejection. Transplantation 1991; 52: 868-73.
99. Homeister JW, Satoh PS, Kilgore KS, Lucchesi BR. Soluble complement receptor type 1 prevents human complement-mediated damage of the rabbit isolated heart. J. Immunol. 1993; 150: 1055-64.
100. Dalmasso AP, L. PJ. Prevention of complement-mediated activation of xenogeneic endothelial cells in an in vitro model of xenograft hyperacute rejection by C1-inhibitor. Transplantation 1993; 56: 1171-6.
101. Dalmasso AP, Platt JL. Potentiation of C1 inhibitor plus heparin in prevention of complement-mediated activation of endothelial cells in a model of xenograft hyperacute rejection. Transplant. Proc. 1994; 26: 1246-7.
102. Robson SC, Candinas D, Hancock WW, Winkler H, Bach FH. Role of endothelial cells in transplantation. Int. Arch. Allergy Immunol. 1995; 106: 305-22.
103. Hunt BJ, Rosenberg RD. The essential role of haemostasis in hyperacute rejection. Xeno. 1993; 1: 16-9.
104. Bach FH, Robson SC, Ferran C et al. Endothelial cell activation and thromboregulation during xenograft rejection. Immunol. Rev. 1994; 141: 5-30.
105. Saadi S, Platt JL. Transient perturbation of endothelial integrity induced by natural antibodies and complement. J. Exp. Med. 1995; 181: 21-31.
106. Platt JL, Vercellotti GM, Lindman BJ, Oegema TR, Bach FH, Dalmasso AP. Release of heparan sulfate from endothelial cells. Implications for pathogenesis of hyperacute rejection. J. Exp. Med. 1990; 171: 1363-8.
107. Coughlan AF, Berndt MC, Dunlop LC, Hancock WW. In vivo studies of P-selectin and platelet-activating factor during endotoxemia, accelerated allograft rejection, and discordant xenograft rejection. Transplant. Proc. 1993; 25: 2930-1.
108. Blakely ML, van Der Werf WJ, Berndt MC, Dalmasso AP, Bach FH, Hancock WW. Activation of intragraft endothelial and mononuclear cells during discordant xenograft rejection. Transplantation 1994; 58: 1059-66.
109. Lesnikoski BA, Shaffer DA, Van der Werf WJ, Hancock WW, Bach FH. Endothelial and host mononuclear cell activation and cytokine expression during rejection of pig-to-baboon discordant xenografts. Transplant. Proc. 1995 (in press).
110. Auchincloss H. Why is cell-mediated xenograft rejection so strong? Xeno. 1995; 3: 19-22.
111. Yamada K, Sachs DH, DerSimonian H. Human anti-porcine xenogeneic T cell response. J. Immunol. 1995; 155: 5249-56.
112. Kirk AD, Li RA, Kinch MS, Abernathy KA, Doyle C, Bollinger RR. The human antiporcine cellular repertoire. Transplantation 1993; 55: 924-31.
113. Kawai T, Cosimi AB, Colvin R et al. Mixed allogeneic chimerism and renal allograft tolerance in cynomolgus monkeys. Transplantation 1995; 59: 256-62.
114. Shabari Y, Aksentijevich I, Sundt TM, Sachs DH, Sykes M. Specific tolerance induction across a xenogeneic harrier: Production of mixed rat/mouse lymphohematopoietic chimeras using a nonlethal preparative regimen. J. Exp. Med. 1990; 172: 195-202.
115. Sykes M, Lee LA, Sachs DH. Xenograft tolerance. Immunol. Rev. 1994; 141: 245-76.
116. Sachs DH. Xenotransplantation: Challenge and opportunity. Xenotransplantatibn 1994; 1: 1-2.
117. Chapman LE, Folks TM, Saloman DR, Patterson AP, Eggerman TE, Noguchi PD. Xenotransplantation and xenogeneic infections. New Engl. J. Med. 1995; 333: 1498-501.
118. Allan JS. Xenotransplantation at a crossroads: Prevention versus progress. Nature Med. 1996; 2: 18-21.
119. Burdick JF, Fair JH. Xenoperfusion: the pig liver as a bridge. Xeno. 1994; 2: 3-7.
120. Makowka L, Cramer DV, Hoffman A, Sher L, Podesta L. Pig liver xenografts as a temporary bridge for human allografting. Xeno. 1993; 1: 27-9.
121. Makowka L, Cramer DV, Hoffman A et al. The use of a pig liver xenograft for temporary support of a patient with fulminant hepatic failure. Transplantation 1995; 59: 1654-9.
122. Groth CG, Korsgren O, Andersson A et al. Evidence of xenograft function in diabetic patient grafted with porcine fetal pancreas. Transplant. Proc. 1992; 24: 972-3.
123. Groth CG, Korsgren O, Tibell A et al. Transplantation of porcine fetal pancreas to diabetic patients. Xeno. 1994; 2: 102-6.